Evolva enters partnership on active pharmaceutical ingredients
Partner to fully fund development of new production routes for a family of APIs
17 August 2016 – Evolva (SIX: EVE) has entered into an agreement with a private US biotech venture to develop new production routes for a family of existing active pharmaceutical ingredients (“API”).
Evolva will be responsible for the development of the production routes, whilst the partner will be responsible for the registration and commercialisation of the resulting products. The partner’s management has many decades of experience in developing and commercialising pharmaceuticals.
The collaboration will both benefit from, and provide benefits to, some of Evolva’s existing product developments and follows Evolva’s strategy of monetising applications outside its focus areas with partners.
Evolva will receive a low single digit million US dollar sum over the next 12 months with later phases potentially increasing this to several tens of millions of dollars in R&D funding. Evolva also receives a 20% equity stake in the partner.
This partnership does not change the revenue guidance for 2016.
– ends –
Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, resveratrol, vanillin, nootkatone and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video.
+ 41 61 485 2005
|Jakob Dynnes Hansen
+ 41 61 485 2034
+ 41 61 485 2035
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.
Stay informed Join our mailing list to receive Evolva’s press releases via e-mail.Join